Federal contractor · public award history
PARTNER THERAPEUTICS, INC.
Parent: PARTNER THERAPEUTICS, INC. Unique Entity Identifier (UEI)J33MSDBJZMC6
- Awards we know about
- 4
- Typical size
- $12.99M
- Middle of their public awards
- Dollars on those awards
- $97.25M
Most of their awards we can see fall roughly between $6.87M and $48.25M.
Continue contractor research
Use the verified identifiers and public award record to investigate documented incumbents, compare competitors, or identify possible teaming partners. This is a research starting point, not a capability or partner recommendation.
These official USAspending contract records do not rate capability or past performance and do not tell you whether to team or bid.
Awarding agencies
- Department of Health and Human Services (3)
- Department of Veterans Affairs (1)
Industries & product codes
Award history
- Department of Health and Human Services$83.52MSep 8, 2025Procurement Instrument Identifier (PIID)75A50323F80027Pharmaceutical Preparation Manufacturing325412Medical And Surgical Instruments, Equipment, And Supplies6515Contract awardUSAspending ↗
LEUKINE 250MCG VIL INJ (5PKG)
- Department of Veterans Affairs—Sep 3, 2025Procurement Instrument Identifier (PIID)36F79723D0171Pharmaceutical Preparation Manufacturing325412Drugs And Biologicals6505Indefinite Delivery Vehicle (IDV)USAspending ↗
65 I B, DRUGS, PHARMACEUTICALS, & HEMATOLOGY RELATED PRODUCTS, FSS CONTRACT AWARD
- Department of Health and Human Services$12.99MAug 8, 2025Procurement Instrument Identifier (PIID)75A50124C00061Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)541715Health R&D Services; Health Care Services; Experimental DevelopmentAN13Contract awardUSAspending ↗
PARTNER THERAPEUTICS: THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO CONFIRM LEUKINE SAFETY IN SEPSIS PATIENTS, INFORM OPTIMAL LEUKINE DOSING, EXPLORE LEUKINE EFFICACY, AS WELL AS ADVANCE DEVELOPMENT OF MONOCYTE HUMAN LEUKOCYTE ANTIGEN-DR (MHLA-DR) AS
- Department of Health and Human Services$748,039Mar 20, 2025Procurement Instrument Identifier (PIID)75A50123C00064Research and Development in Biotechnology (except Nanobiotechnology)541714Health R&D Services; Health Care Services; Expenses For R&D Facilities And Major EquipmentAN15Contract awardUSAspending ↗
R&D FOR REPURPOSING FX06, A HOST-DIRECTED THERAPY, FOR TREATMENT OF SEVERE DISEASE IN PATIENTS WITH SUDAN VIRUS DISEASE (SVD) OR OTHER FILOVIRUSES AOI #22 REBOOT
For research only. This is not legal advice, a past-performance review, or a recommendation to team or bid. Check USAspending and SAM.gov.